NASDAQ: ADXNAddex Therapeutics Ltd Stock
$19.28-0.77 (-3.84%)
Updated Apr 22, 2024
ADXN Price
$19.28
Fair Value Price
-$0.10
Market Cap
$19.31M
52 Week Low
$5.00
52 Week High
$27.90
P/E
-123.59x
P/B
15.17x
P/S
1.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.83M
Earnings
-$12.57M
Gross Margin
100%
Operating Margin
-620.33%
Profit Margin
-640.9%
Debt to Equity
3.05
Operating Cash Flow
-$10M
Beta
0.36
Next Earnings
Apr 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ADXN Overview
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADXN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADXN ($19.28) is overvalued by 18,477.47% relative to our estimate of its Fair Value price of -$0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ADXN ($19.28) is not significantly undervalued (18,477.47%) relative to our estimate of its Fair Value price of -$0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADXN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADXN due diligence checks available for Premium users.
Be the first to know about important ADXN news, forecast changes, insider trades & much more!
ADXN News
Valuation
ADXN fair value
Fair Value of ADXN stock based on Discounted Cash Flow (DCF)
Price
$19.28
Fair Value
-$0.10
Undervalued by
18,477.47%
ADXN ($19.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADXN ($19.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADXN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADXN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-123.59x
Industry
16.21x
Market
41x
ADXN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.17x
Industry
5.82x
ADXN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADXN's financial health
Profit margin
Revenue
$218.8k
Net Income
-$3.4M
Profit Margin
-1,554.1%
ADXN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADXN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.5M
Liabilities
$4.2M
Debt to equity
3.05
ADXN's short-term assets ($4.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADXN's short-term assets ($4.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADXN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADXN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$741.7k
Investing
-$1.4k
Financing
-$69.5k
ADXN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADXN vs Biotech Stocks
Addex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.